Latest news with #Regencell
CNBC
3 hours ago
- Business
- CNBC
Nasdaq-traded Chinese herb company hits near $30 billion market value after speculative surge
Regencell Bioscience Holdings, an early-stage, Hong Kong-based bioscience company with no revenue, is the latest speculative overseas stock to attract an unusual surge in trading demand. Shares of Regencell, which says it develops traditional Chinese herb treatments to treat childhood attention deficit hyperactivity disorder and autism, more than tripled on Monday — soaring more than 280% by the close. A 38-for-1 split declared on June 2 took effect on Monday. The company's year to date performance is off the charts too, having risen 46,000% in 2025. By Monday's close, Regencell, founded in 2014 and traded on Nasdaq under the ticker 'RGC' since 2021, had a total market capitalization of $29.7 billion, according to S&P Capital IQ. Regencell CEO Yat-Gai Au controls 86.24% of the total number of shares outstanding, according to FactSet data. Regencell is the latest example of a speculative international stock attracting attention during summer trading. In August, 2022, for example, AMTD Digital, a Hong Kong-based fintech company, climbed 126%, briefly giving it a market value greater than Coca-Cola and Bank of America. Regencell's market value is now about equal with Nasdaq-traded Lululemon and tops Super Micro Computer and Fifth Third Bancorp. Earlier this month, Regencell explained the stock split as designed solely "to enhance liquidity in the market for the company's ordinary shares and make the shares more accessible to investors." Stock splits do not change anything fundamentally about a company. Regencell's surge also came amid an increased focus on alternative medicines after Robert F. Kennedy Jr. was sworn in as Secretary of the U.S. Department of Health and Human Services in February. Kennedy, a vaccine skeptic, has taken steps to discourage routine immunizations in the U.S., last week removing all of the members of a panel that advises the Centers for Disease Control and Prevention on vaccines. Regencell's stock often makes huge one-day swings. For example, shares jumped roughly 30% on March 21, before dropping 30% the following trading day. In spite of the wild spike in the stock, little is known about the efficacy and commercialization of the Regencell's treatments for ADHD and Autistic Spectrum Disorders. Regencell's business centers on a proprietary Traditional Chinese Medicine formula (TCM) developed in a partnership with TCM practitioner Sik-Kee Au using his "Sik-Kee Au TCM Brain Theory." Sik-Kee Au is the father of the Regencell chief executive officer Yat-Gai Au, the company said in a 2022 statement. Three liquid-based, orally TCM formulae candidates claim to address mild, moderate and severe conditions and only contain natural ingredients such as so-called "detoxication herbs," blood circulation herbs and digestion herbs. "These TCM formulae form the basis of our TCM product candidates, which we intend to develop and commercialize for the treatment of ADHD and ASD," Regencell's website reads. In its latest annual report filed last October, Regencell said that it had not generated any revenue, nor filed for any regulatory approvals of its TCM formulas. For the fiscal years ended June 2024 and 2023, Regencell incurred total net losses of $4.36 million and $6.06 million, respectively, according to a 20F filing to the SEC. "We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable," read the filing. Regencell has not responded to a CNBC request for comment. Regencell's latest patient case study, dated Nov. 15, 2023, said 28 patients were given the treatment over a period of three months in a second efficacy trial and showed an improvement in symptoms of ADHD and ASD, according to the company's webpage. In an earlier case, Regencell said in a 2021 news release that it treated a dozen patients with suspected or confirmed Covid-19 cases, using a modified version of Au's modified proprietary cold and flu TCM formula. What was described as an improvement of Covid conditions led Regencell to form a joint venture with Honor Epic Enterprises Limited in Sept. 2021 to conduct further tests and commercialize the company's Covid treatment in ASEAN countries, according to the statement. The stock has attracted little chatter on social media over the past few years. Those comments that have been made suggest both retail trader enthusiasm — and skepticism. One user on the Reddit page "r/Shortsqueeze" wrote on Monday that Regencell is "trading like a meme coin. Bought a little to see what happens and it dropped 50% right after lol." Another user said in a post made three months ago, "I scalp RGC everyday for a bit of profit." The stock jumped 1,360% in May alone. On LinkedIn in May, one investor said he "can't stop laughing," after reading the company description. Another post from a user in the pharmaceutical industry, according to his profile, last week said Regencell has become the "stock to watch" after its spike in May on "no official news or catalysts." Another LinkedIn user last month commented on Regencell, saying, "China based, low volume and no official news, bizarro." On X, one user wrote in a Monday post said, "for #CompleteBullsh__CompanyOfTheYear I nominate regencell."
Straits Times
7 hours ago
- Business
- Straits Times
Nasdaq-listed herbal medicine stock with no sales rallies 64,000%
The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than US$20 billion (S$25.6 billion) in market value. PHOTO: ST FILE NEW YORK - A Nasdaq-listed stock focused on herbal medicine has spiked by more than 64,000 per cent so far in 2025 and yet, the company itself has made zero revenue – much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings, a penny stock as recently as April, to one worth more than US$20 billion (S$25.6 billion) in market value. A year ago, the stock had a market capitalisation of just US$53 million. This is despite the company having a net loss of US$4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Earlier in June the company said its board approved a 38-for-1 stock split. When the split took effect on June 16, shares soared as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 640-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission (SEC). A representative for Regencell didn't immediately respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders like ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components.' 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering, the SEC filing showed. It said its gross proceeds from its IPO were US$21.85 million, with additional net proceeds of US$2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6 per cent of shares, compared to Apple – which has about 98 per cent available – and Tesla's 87 per cent. Insiders own the remaining Regencell shares, with chief executive officer Yat-Gai Au's ownership accounting for 86 per cent, according to holding data compiled by Bloomberg. BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Times
10 hours ago
- Business
- Business Times
Herbal medicine stock with no sales rallies 64,000%
[NEW YORK] A biotech stock focused on herbal medicine has surged by more than 64,000 per cent so far this year and yet, the company itself has made zero revenue – much less turned a profit. The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth more than US$20 billion in market value. A year ago, the stock had a market capitalisation of just US$53 million. This is despite the company having a net loss of US$4.4 million for its fiscal year that ended June 2024, a 28 per cent decrease from the previous year. Earlier this month the company said its board approved a 38-for-1 stock split. When the split took effect on Monday (Jun 16), shares rose as much as 434 per cent – their biggest one-day jump ever – to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 640-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission (SEC). A representative for Regencell did not immediately respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders such as ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components'. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid-19 symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering (IPO), the SEC filing showed. It said its gross proceeds from its IPO were US$21.85 million, with additional net proceeds of US$2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6 per cent of shares, compared to Apple – which has about 98 per cent available – and Tesla's 87 per cent. Insiders own the remaining Regencell shares, with chief executive officer Yat-Gai Au's ownership accounting for 86 per cent, according to holding data compiled by Bloomberg. BLOOMBERG
Yahoo
13 hours ago
- Business
- Yahoo
Regencell Bioscience Stock Skyrockets as 38-to-1 Split Takes Effect
Regencell Bioscience Holdings shares took off when a 38-to-1 stock split went into effect. The biotech that does research to treat children's diseases using traditional Chinese medicine announced the forward stock split June 2. Regencell said the split was designed to "enhance liquidity" and "make the shares more accessible to investors."It's been quite a good month for investors in Regencell Bioscience Holdings (RGC). Shares of the Hong Kong-firm that focuses on the use of traditional Chinese medicine to treat Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) in children more than quadrupled on the first day a huge 38-to-1 stock split took effect. The company announced the split June 2, and that the stock would be distributed June 13. Regencell said the move was intended to "enhance liquidity in the market for the Company's ordinary shares and make the shares more accessible to investors." Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Herbal Medicine Stock With No Sales Rallies 64,000%
(Bloomberg) — A biotech stock focused on herbal medicine has surged by more than 46,000% so far this year and yet, the company itself has made zero revenue — much less turned a profit. As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space As American Architects Gather in Boston, Retrofits Are All the Rage The unbelievable rally has transformed Regencell Bioscience Holdings Limited, a penny stock as recently as April, to one worth nearly $30 billion in market value. A year ago, the stock had a market capitalization of just $53 million. This is despite the company having a net loss of $4.4 million for its fiscal year that ended June 2024, a 28% decrease from the previous year. Earlier this month the company said its board approved a 38-for-1 stock split. When the split took effect Monday, shares rose 283% — their biggest one-day jump in nearly a year on a closing basis — to a record high, triggering more than 10 volatility halts. Shares of the company have been on a bizarre, 460-fold tear in 2025, with little to no news from the firm. The Hong Kong-based firm, which debuted on the Nasdaq Capital Market in 2021, is in the research and development stage and has not generated any revenue since inception, according to its most-recent annual filing with the US Securities and Exchange Commission. A representative for Regencell didn't respond to a Bloomberg News request for comment. Incorporated in the Cayman Islands, the firm aims to treat neurological disorders like ADHD and autism spectrum disorder through traditional herb-based medicines, according to its website. Its traditional Chinese medicine (TCM) formula, which forms the basis of its product candidates, 'contains only natural ingredients without any synthetic components.' 'We have not generated revenue from any TCM formulae candidates or applied for any regulatory approvals, nor have distribution capabilities or experience or any granted patents or pending patent applications and may never be profitable,' the company said in an October filing. The company also made its foray into treatments for Covid-19, conducting trials in 2022 for an 'holistic approach' with its experimental therapy. Regencell said data from a 2022 trial showed the treatment was effective in reducing and eliminating Covid symptoms within six days, although the results were yet to be peer-reviewed. The firm has funded its operations so far, primarily from shareholder loans and proceeds from its initial public offering, the SEC filing showed. It said its gross proceeds from its IPO were $21.85 million, with additional net proceeds of $2.85 million from the issue of the over allotment shares and exercise of 325,000 shares. One potential reason for the outsized swings in Regencell shares: its tiny float. Of its nearly 500 million outstanding shares, only about 30 million are available to be traded. That equates to roughly 6% of shares, compared to Apple Inc. — which has about 98% available — and Tesla Inc.'s 87%. Insiders own the remaining Regencell shares, with Chief Executive Officer Yat-Gai Au's ownership accounting for 86%, according to holding data compiled by Bloomberg. (Updates with closing prices throughout.) American Mid: Hampton Inn's Good-Enough Formula for World Domination The Spying Scandal Rocking the World of HR Software How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants US Allies and Adversaries Are Dodging Trump's Tariff Threats As Companies Abandon Climate Pledges, Is There a Silver Lining? ©2025 Bloomberg L.P. Inicia sesión para acceder a tu cartera de valores
